Nicola P Klein1, Paula Peyrani2, Kari Yacisin3, Nicole Caldwell4, Xia Xu5, Ingrid L Scully6, Daniel A Scott7, Kathrin U Jansen8, William C Gruber9, Wendy Watson10. 1. Kaiser Permanente Vaccine Study Center, Oakland, CA 94612, USA. Electronic address: Nicola.Klein@kp.org. 2. Vaccine Medical Development and Scientific/Clinical Affairs, Pfizer Inc, Collegeville, PA 19426, USA. Electronic address: Paula.Peyrani@pfizer.com. 3. Vaccine Research and Development, Pfizer Inc, Collegeville, PA 19426, USA. Electronic address: Kari.Yacisin@pfizer.com. 4. Vaccine Research and Development, Pfizer Inc, Collegeville, PA 19426, USA. Electronic address: Nicole.Caldwell@pfizer.com. 5. Vaccine Research and Development, Pfizer Inc, Collegeville, PA 19426, USA. Electronic address: Xia.Xu3@pfizer.com. 6. Vaccine Research and Development, Pfizer Inc, Pearl River, NY 10965, USA. Electronic address: Ingrid.Scully@pfizer.com. 7. Vaccine Research and Development, Pfizer Inc, Collegeville, PA 19426, USA. Electronic address: Dan.Scott@pfizer.com. 8. Vaccine Research and Development, Pfizer Inc, Pearl River, NY 10965, USA. Electronic address: Kathrin.Jansen@pfizer.com. 9. Vaccine Research and Development, Pfizer Inc, Pearl River, NY 10965, USA. Electronic address: bill.gruber@pfizer.com. 10. Vaccine Research and Development, Pfizer Inc, Collegeville, PA 19426, USA. Electronic address: wendy.watson2@pfizer.com.
Abstract
INTRODUCTION: Introduction of pneumococcal conjugate vaccines (PCVs), including the 13-valent PCV (PCV13), has considerably reduced pneumococcal disease burden. However, additional serotypes not in PCV13 continue to present a substantial disease burden. The 20-valent PCV (PCV20) was developed to expand protection against pneumococcal disease beyond PCV13. As part of the phase 3 clinical development program, the current study assessed consistency of immune responses across 3 lots of PCV20 and described the safety profile of PCV20. METHODS: This phase 3, randomized, multicenter, double-blind study of pneumococcal vaccine-naive adults 18-49 years of age randomized 1710 participants in a 2:2:2:1 ratio to receive 1 of 3 lots of PCV20 or PCV13. Immunogenicity was assessed through serotype-specific opsonophagocytic activity (OPA) titers before and approximately 1 month (28-42 days) after vaccination. Reported local reactions within 10 days, systemic events within 7 days, adverse events (AEs) within 30 days, and serious AEs (SAEs) and newly diagnosed chronic medical conditions (NDCMCs) within 6 months after vaccination were evaluated. RESULTS: Equivalence in immune responses (OPA geometric mean titers) for all 20 vaccine serotypes was demonstrated across the 3 PCV20 lots. Robust responses, assessed by OPA geometric mean fold rises, percentage of participants achieving ≥4-fold rises, and percentage of participants with OPA titers ≥lower limit of quantitation, were observed after PCV20. Reported rates of local reactions, systemic events, and AEs were similar between the pooled PCV20 lots and PCV13; most events were mild or moderate. Reported rates of SAEs and NDCMCs were low and similar between the PCV20 and PCV13 groups. CONCLUSIONS: Three different lots of PCV20 demonstrated robust and consistent immunogenicity. The safety and tolerability of PCV20 was acceptable and similar to that of PCV13. (Clinicaltrials.gov: NCT03828617).
INTRODUCTION: Introduction of pneumococcal conjugate vaccines (PCVs), including the 13-valent PCV (PCV13), has considerably reduced pneumococcal disease burden. However, additional serotypes not in PCV13 continue to present a substantial disease burden. The 20-valent PCV (PCV20) was developed to expand protection against pneumococcal disease beyond PCV13. As part of the phase 3 clinical development program, the current study assessed consistency of immune responses across 3 lots of PCV20 and described the safety profile of PCV20. METHODS: This phase 3, randomized, multicenter, double-blind study of pneumococcal vaccine-naive adults 18-49 years of age randomized 1710 participants in a 2:2:2:1 ratio to receive 1 of 3 lots of PCV20 or PCV13. Immunogenicity was assessed through serotype-specific opsonophagocytic activity (OPA) titers before and approximately 1 month (28-42 days) after vaccination. Reported local reactions within 10 days, systemic events within 7 days, adverse events (AEs) within 30 days, and serious AEs (SAEs) and newly diagnosed chronic medical conditions (NDCMCs) within 6 months after vaccination were evaluated. RESULTS: Equivalence in immune responses (OPA geometric mean titers) for all 20 vaccine serotypes was demonstrated across the 3 PCV20 lots. Robust responses, assessed by OPA geometric mean fold rises, percentage of participants achieving ≥4-fold rises, and percentage of participants with OPA titers ≥lower limit of quantitation, were observed after PCV20. Reported rates of local reactions, systemic events, and AEs were similar between the pooled PCV20 lots and PCV13; most events were mild or moderate. Reported rates of SAEs and NDCMCs were low and similar between the PCV20 and PCV13 groups. CONCLUSIONS: Three different lots of PCV20 demonstrated robust and consistent immunogenicity. The safety and tolerability of PCV20 was acceptable and similar to that of PCV13. (Clinicaltrials.gov: NCT03828617).
Authors: Redouane Abouqal; Maher Beji; Mohamed Chakroun; Kamal Marhoum El Filali; Jihane Rammaoui; Hela Zaghden Journal: Front Public Health Date: 2022-07-01
Authors: Miwako Kobayashi; Jennifer L Farrar; Ryan Gierke; Amadea Britton; Lana Childs; Andrew J Leidner; Doug Campos-Outcalt; Rebecca L Morgan; Sarah S Long; H Keipp Talbot; Katherine A Poehling; Tamara Pilishvili Journal: MMWR Morb Mortal Wkly Rep Date: 2022-01-28 Impact factor: 35.301
Authors: I Passaris; N Mauder; M Kostrzewa; I Burckhardt; S Zimmermann; N M van Sorge; H-C Slotved; S Desmet; P-J Ceyssens Journal: J Clin Microbiol Date: 2022-06-14 Impact factor: 11.677
Authors: Maria Certan; Hannah M Garcia Garrido; Gino Wong; Jarom Heijmans; Martin P Grobusch; Abraham Goorhuis Journal: Clin Infect Dis Date: 2022-09-29 Impact factor: 20.999